// App-Quantinova.ai

4123 : Overall survival of patients with pancreatic adenocarcinoma and BRCA1 or BRCA2 germline mutation.

Researchers

Presenter

  • Kyaw Lwin Aung

Principal Investigators

  • Spring Holter

  • Ayelet Borgida

  • Ashton Connor

  • Melania Pintilie

  • Neesha C. Dhani

  • David W. Hedley

  • Jennifer J. Knox

  • Steven Gallinger

Medical Centers

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, ON, Canada

  • Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, University of Toronto, Mount Sinai Hospital-Lunenfeld Research Institute, Toronto, ON, Canada

  • Ontario Institute for Cancer Research, Toronto, ON, Canada

  • Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Princess Margaret Cancer Centre, University Health Network, Division of Medical Oncology and Hematology, Toronto, ON, Canada

  • Ontario Cancer Institute, Princess Margaret Hospital, Toronto, ON, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Department of Surgery, Toronto General Hospital, University of Toronto, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreatic cancer

  • Solid malignancies

  • Microphthalmia, syndromic, 9

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Breast cancer type 2 susceptibility protein

Drug/Treatment

  • N/A

Outcome

  • Positive

Study Design

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved